Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1152 studies found for:    glioblastoma
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Terminated
Has Results
TRC105 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: TRC105
2 Completed A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Intervention: Drug: MEDI-575
3 Unknown  A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Condition: Glioblastoma
Intervention: Procedure: FDG-PET
4 Recruiting Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study
Condition: Glioblastoma Multiforme
Interventions: Dietary Supplement: Ketogenic diet;   Dietary Supplement: Standard diet
5 Recruiting Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: F-MISO;   Other: Cerebral magnetic resonance imagery;   Drug: Bevacizumab;   Other: Clinical examination
6 Completed Evaluation of [18F]-FMISO for Non Operated Glioblastoma
Condition: Glioblastoma
Intervention: Procedure: 18F]-FMISO PET-CT
7 Active, not recruiting Disease Progression and Treatment-induced Alterations in Glioblastoma
Condition: Brain Tumor
Intervention: Genetic: analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
8 Recruiting Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study
Condition: Glioblastoma Multiforme
Intervention: Other: ketogenic diet
9 Withdrawn A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
Condition: Recurrent Glioblastoma
Interventions: Drug: TMZ plus concurrent re-irradiation;   Drug: Temozolomide
10 Recruiting Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Intervention: Radiation: Radiochemotherapy
11 Terminated Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Intervention: Drug: TLN-4601
12 Recruiting Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid
Condition: Glioblastoma
Intervention: Other: Platelet level determination
13 Recruiting Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
Condition: Glioblastoma Multiforme
Intervention: Drug: PQR309
14 Completed PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Condition: Glioblastoma
Interventions: Drug: PTK787/ZK 222584;   Drug: Temozolomide;   Procedure: Radiation Therapy
15 Recruiting Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Conditions: Glioblastoma;   Recurrent Glioblastoma;   Brain Tumor
Intervention: Drug: Tesevatinib
16 Unknown  Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
Condition: Glioblastoma
Intervention: Drug: Temozolomide
17 Completed Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
Condition: Glioblastoma
Intervention: Radiation: Magnetic Resonance Imaging (MRI)
18 Completed Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma
Condition: Glioblastoma
Intervention: Drug: nelfinavir
19 Recruiting Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
Condition: Glioblastoma
Intervention: Biological: Personalized cellular vaccine
20 Terminated
Has Results
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme
Interventions: Drug: Everolimus;   Procedure: Surgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.